Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

FDA approves first gene therapy for rare pediatric immune disorder

Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years.

27 Mar 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

Scientists reveal how light-activated drugs change receptor activity

Rendering a drug effective or ineffective in a flash at the appropriate location – this is the focus of research in photopharmacology.

19 Mar 2026

Study uncovers how tuberculosis bacteria fuel themselves during infection

Researchers at The Hospital for Sick Children (SickKids) have uncovered how the bacteria that causes tuberculosis fuels itself during infection, providing new insights into one of the world's deadliest infectious diseases.

17 Mar 2026

Brain breathing mechanism linked to persistent high blood pressure

A brain mechanism may explain why approximately 40% of people with hypertension continue to have high blood pressure despite taking medication. The discovery reveals potential targets for new treatments.

16 Mar 2026

Does coffee disrupt sleep? Large population study suggests the impact may be minimal

A large cross-sectional analysis of 25,381 Swedish adults aged 50–64 found that habitual coffee consumption showed only very weak associations with sleep quality and daytime sleepiness. Genetic analyses confirmed known coffee-related variants and suggested that long-term caffeine exposure may lead to adaptation in the brain’s adenosine signaling system.

11 Mar 2026

Cellular energy changes may help detect early-stage major depression

Researchers may have discovered a new way to diagnose and treat major depression at the earliest stage of the condition, giving patients the best opportunity for recovery.

10 Mar 2026

ATP delivery fixes dysfunctional dopamine packaging in Parkinson's neurons

A new study shows how dysfunctional packaging of the neurotransmitter dopamine triggers toxic processes in neurons - and how this can be repaired with simple delivery of energy (ATP).

2 Mar 2026

Identifying the core catalyst for muscle energy production

Researchers have investigated the role of a certain enzyme in regulating energy in muscle and exercise performance for decades, but a new study by Virginia Tech scientists has identified more precisely than ever how this mechanism works.

26 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Study reveals coffee triggers distinct cytokine responses compared with pure caffeine

A randomized crossover pilot study in healthy adults found that coffee and isolated caffeine produce distinct short-term immune responses despite equivalent caffeine doses. The results suggest non-caffeine coffee compounds may influence cytokine activity and caffeine metabolism, although findings remain preliminary due to the small sample size.

19 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Study explores how reversible RNA editing could transform future cardiovascular medicine

This mini-review synthesises evidence showing that adenosine-to-inosine RNA editing plays an important regulatory role in cardiovascular development, cellular homeostasis, and disease biology. It highlights emerging links between dysregulated RNA editing and cardiovascular conditions while outlining biomarker potential and reversible RNA-editing therapeutic strategies that remain under investigation.

15 Feb 2026

Parkinson's-related weight loss reflects a failure of the body's energy-producing pathways

Weight loss is a well-recognized but poorly understood non-motor feature of Parkinson's disease (PD). Many patients progressively lose weight as the disease advances, often alongside worsening motor symptoms and quality of life.

13 Feb 2026

Transcription factor HOXD13 drives melanoma growth and immune evasion

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade attack by the body's immune system, a new study shows.

11 Feb 2026

Daily coffee intake linked to fewer atrial fibrillation relapses

The study reveals that moderate coffee consumption may lower atrial fibrillation recurrence risk post-cardioversion, highlighting coffee's potential benefits.

30 Jan 2026

Following the EAT-Lancet diet lowers chronic kidney disease risk

Research shows the EAT-Lancet diet may lower chronic kidney disease risk, emphasizing the importance of diet quality and personalized nutrition in prevention.

28 Jan 2026

Tiny plastic particles may interfere with brain processes implicated in Parkinson’s disease

Micro- and nanoplastics are increasingly detected in human tissues, including the brain, and experimental evidence suggests they can interact with biological pathways central to Parkinson’s disease pathology. This review synthesises mechanistic data indicating that plastic particles may influence protein aggregation, neuroinflammation, mitochondrial dysfunction, and the gut–brain axis, while emphasising the need for prospective human studies.

26 Jan 2026

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene called EGFR (epidermal growth factor receptor).

21 Jan 2026

The gut is not just digestive and new evidence shows it actively controls brain function

This comprehensive review synthesizes a decade of human and animal research to explain how the gut and brain communicate through hormonal, neural, immune, and microbial pathways. It highlights how disruptions in these pathways contribute to gastrointestinal, metabolic, and neurological disorders, and how modern therapies are beginning to exploit gut–brain signaling for clinical benefit.

6 Jan 2026